22 results
Thumbnail

D2.271 - The effect of Organic Light Emiting Diode(OLED) phototherapy in atopic mouse model

Thumbnail

D2.274 - Late-onset toxic epidermal necrolysis (TEN) associated with nivolumab: attention to possible cofactors

Thumbnail

D2.261 - Mental health and quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.265 - Standard dosage vs. increased dosage of non-sedating antihistamines in pharmacotherapy of chronic spontaneous urticaria

Thumbnail

D2.266 - Comparative Efficacy of Dupilumab, Janus Kinase Inhibitors, and Conventional Immunosuppressants on Neuropsychiatric Outcomes in Patients with Atopic Dermatitis: A Retrospective Cohort Study

Thumbnail

D2.267 - Real-World Clinical Outcomes of Chronic Urticaria Patients in Greece: Longitudinal Data from the CURE Registry

Thumbnail

D2.268 - Clinical characteristics and Therapeutic Management of Hereditary Angioedema due to C1-Inhibitor Deficiency: A Retrospective Cohort Study in Colombia

Thumbnail

D2.269 - Predictors of Poor Disease Control in Greek Patients with Chronic Urticaria: Real-World Evidence from the CURE Registry

Thumbnail

D2.270 - Clinical and Laboratory predictors of treatment response among adult Egyptian patients with Chronic Spontaneous Urticaria

Thumbnail

D2.272 - Long-Term Remission Patterns in Chronic Spontaneous Urticaria: A Real-Life Cohort Study

Thumbnail

D2.273 - The frequency of metal sensitisation in patients who are about to undergo joint replacement

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial